Determination of gemifloxacin in different tissues of rat after oral dosing of gemifloxacin mesylate by LC-MS/MS and its application in drug tissue distribution study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 2, 2010, Pages 216-226

  Roy, Bikash ^a   Das, Ayan ^a   Bhaumik, Uttam ^a   Sarkar, Amlan Kanti ^a   Bose, Anirbandeep ^a   Mukharjee, Jayanti ^a   Chakrabarty, Uday Sankar ^a   Das, Anjan Kumar ^a   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Gemifloxacin; LC MS MS; Quantification; Tissue distribution; Validation

Indexed keywords

CIPROFLOXACIN; FORMIC ACID; GEMIFLOXACIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ARTICLE; BRAIN TISSUE; CALIBRATION; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; FLOW RATE; FRAGMENTATION REACTION; HEART; KIDNEY PARENCHYMA; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; LIVER; LUNG PARENCHYMA; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; QUALITY CONTROL; RAT; STOMACH; TESTIS; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FLUOROQUINOLONES; FREEZING; MALE; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; NAPHTHYRIDINES; QUALITY CONTROL; RATS; RATS, WISTAR; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 77349092254     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.12.019     Document Type: Article

References (17)

1. Ball P. J. Antimicrob. Chemother. 2000, 46:17-24.
2. Mandell L. J. Antimicrob. Chemother. 2000, 46:33-37.
3. Cormican M.G., Jones R.N. Antimicrob. Agents Chemother. 1997, 41:204-211.
4. Erwin M.E., Jones R.N. J. Clin. Microbiol. 1999, 37:279-280.
5. Johnson D.M., Jones R.N., Erwin M.E. Diagn. Microbiol. Infect. Dis. 1999, 33:87-91.
6. Berry V., Page R., Satterfield J., Singley C., Straub R., Woodnutt G. J. Antimicrob. Chemother. 2000, 45:79-85.
7. Hannan P., Woodnutt G. Antimicrob. Agents Chemother. 2000, 45:367-369.
8. Saravolatz L.D., Leggett J. Clin. Infect. Dis. 2003, 37:1210-1215.
9. Drusano G.L., Preston S.L., Owens R.C., Ambrose P.G. Clin. Infect. Dis. 2001, 33:2091-2092.
10. Schentag J.J., Gilliland K.K., Paladino J.A. Clin. Infect. Dis. 2001, 32:S39-S46.
11. Anti-Infective Drugs Advisory Committee Factive (gemifloxacin), US Food and Drug Administration. (04.03.03). http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.
12. Cottagnoud P., Acosta F., Cottagnoud M., Tauber M.G. Antimicrob. Agents Chemother. 2002, 46:1607-1609.
13. Doyle E., Fowles S.E., Mcdonnell D.F., Mccarthy R. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2000, 746:191-198.
14. Allen A., Bygate E., Vousden M., Oliver S., Johnson M., Ward C. Antimicrob. Agents Chemother. 2001, 45:540-545.
15. Allen A., Bygate E., Oliver S., Johnson M., Ward C., Cheon A.J., Choo Y.S., Kim I.C. Antimicrob. Agents Chemother. 2000, 44:1604-1608.
16. Food and Drug Administration of the United States, Guidance for Industry-Bioanalytical Method Validation, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). (May 2001). http://www.fda.gov/cder/guidance/index.htm.
17. Bhaumik U., Ghosh A., Sarkar A.K., Bose A., Selvan P.S., Sengupta P., Shakraborty U.S., Ghosh D., Pal T.K. J. Pharm. Biomed. Anal. 2008, 48:1404-1410.